![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » MELANOMA PATIENTS COMPLETE TREATMENT IN CANCER DRUG TRIAL
MELANOMA PATIENTS COMPLETE TREATMENT IN CANCER DRUG TRIAL
Provectus Pharmaceuticals has announced that the first patients have completed treatment in its Phase I clinical trial of PV-10, also known as Provecta. PV-10 is being evaluated for safety and preliminary efficacy in 20 subjects with Stage III metastatic melanoma, which is the most aggressive form of skin cancer.
The study is being conducted at two of the world's leading melanoma treatment and research centers, both located in New South Wales, Australia, a country where the incidence of melanoma is more than twice that of the U.S.
Each patient enrolled in the study is having one to three tumors treated with a single injection of PV-10 and the local response to the treatment is then being observed for a period of 12 to 24 weeks. Potential effects on nearby untreated tumors (called a "bystander effect") will also be monitored. It is anticipated that the full study will be finished early next year.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct